SELLAS Life Sciences Group, Inc. (SLS) Covered Calls

You can sell covered calls on SELLAS Life Sciences Group, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for SLS (prices last updated Fri 4:16 PM ET):

SELLAS Life Sciences Group, Inc. (SLS) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.38 -0.08 2.38 2.49 160K - 0.0
Covered Calls For SELLAS Life Sciences Group, Inc. (SLS)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 16 2.5 0.20 2.29 8.7% 144%
Jan 20 2.5 0.35 2.14 16.4% 105%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

SELLAS Life Sciences Group, Inc., a development-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S, a cancer immunotherapeutic agent for the treatment of hematologic cancers and solid tumor indications, including acute myeloid leukemia, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, immune combo, and chronic myelogenous leukemia. It also develops NEUVAX, which is in Phase II clinical trial for the treatment of breast cancer; and Anagrelide controlled release, which has completed various clinical trials for the treatment of thrombocythemia. The company has collaboration and license agreements with Memorial Sloan Kettering Cancer Center, Advaxis Immunotherapies, Merck & Co., Inc., National Cancer Institute, and the University of Texas M.D. Anderson Cancer Center. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York